Research Examines Factors That Affect Discontinuation Of TB Preventive Therapy

Infectious Disease Advisor (7/10, Kuhns) reports research found that “time to discontinuation of tuberculosis (TB) preventive therapy does not significantly differ between patients with latent TB infection on 3-month regimens of isoniazid plus rifapentine vs 4-month regimens of rifampin.” But, “patients on isoniazid plus rifapentine often discontinue therapy due to treatment-related adverse events or a joint patient-provider decision to stop, whereas those on rifampin often discontinue therapy due to social and congregate risk factors.” The findings were published in Open Forum Infectious Diseases.